After three years of courtship (and turndowns), Merck pounced on the first glance of clinical data in $1.85B Pandion takeover
It’s almost become cliché for biotech executives to talk about the importance of keeping your options open and being prepared to go all the way …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
